The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical...
Abufaraj M., Kimura S., Haitel A., Iwata T., Isleem U., D'Andrea D., Soria F., Mori K., Rink M., Bensalah K., Rouprêt M., Margulis V., Briganti A., Karakiewicz P. I., Shariat Sh.
Urologic Oncology
Vol.38, Issue8, P. 685.e17-685.e25
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.1016/j.urolonc.2020.03.030
Аннотация:
Background: To evaluate the expression pattern and prognostic role of the urokinase-type plasminogen activator (uPA) system in patients who underwent radical nephroureterectomy (RNU) for nonmetastatic upper tract urothelial carcinoma (UTUC). Methods: A total of 732 patients who were treated with RNU for clinically nonmetastatic UTUC comprised our analytical cohort. Immunohistochemical staining of uPA, uPA receptor (uPAR) and uPA inhibitor (PAI-1) was performed using Murine IgG1 monoclonal antibodies. Outcomes of interest were recurrence-free survival, cancer-specific survival, and overall survival. Results: The median age of the patients was 69.8 years and 56.6[%] of them were males. Overall, overexpression of uPA, uPAR, and PAI-1 was observed in 292 (39.9[%]), 346 (47.3[%]), and 345 (47.1[%]) patients, respectively. The uPA system components showed a statistically significant association with adverse clinicopathologic features such as lymphovascular invasion, multifocality, sessile tumors, an
Ключевые слова:
Biomarkers; Predictors; Survival; Upper tract urothelial carcinoma; Urokinase plasminogen activator; Urothelial carcinoma
immunoglobulin G1 antibody; plasminogen activator inhibitor; urokinase; urokinase receptor; adjuvant chemotherapy; adult; adverse outcome; aged; Article; cancer prognosis; cancer recurrence; cancer specific survival; cancer staging; cancer survival; cohort analysis; female; follow up; human; human tissue; immunohistochemistry; lymph node dissection; lymph vessel metastasis; major clinical study; male; nephroureterectomy; outcome assessment; overall survival; predictive value; priority journal; protein expression; recurrence free survival; retrospective study; tissue microarray; transitional cell carcinoma; treatment planning
Язык текста: Английский
ISSN: 1873-2496
Abufaraj M.
Kimura S.
Haitel A.
Iwata T.
Isleem U.
D'Andrea D.
Soria F.
Mori K.
Rink M.
Bensalah K.
Rouprêt M.
Margulis V. Vitalij 1975-
Briganti A.
Karakiewicz P. I.
Shariat Sh. Sharokh 1973-
Абуфарай М.
Кимура С.
Хаител А.
Иwата Т.
Ислеем У.
Д'Андреа Д.
Сориа Ф.
Мори К.
Ринк М.
Бенсалах К.
Роупрêт М.
Маргулис В. Виталий 1975-
Бриганти А.
Каракиеwиcз П. И.
Шариат Ш. Шарох 1973-
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy
The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical...
Текст визуальный непосредственный
Urologic Oncology
Elsevier Science Publisher B.V.
Vol.38, Issue8 P. 685.e17-685.e25
2020
Статья
Biomarkers Predictors Survival Upper tract urothelial carcinoma Urokinase plasminogen activator Urothelial carcinoma
immunoglobulin G1 antibody plasminogen activator inhibitor urokinase urokinase receptor adjuvant chemotherapy adult adverse outcome aged Article cancer prognosis cancer recurrence cancer specific survival cancer staging cancer survival cohort analysis female follow up human human tissue immunohistochemistry lymph node dissection lymph vessel metastasis major clinical study male nephroureterectomy outcome assessment overall survival predictive value priority journal protein expression recurrence free survival retrospective study tissue microarray transitional cell carcinoma treatment planning
Background: To evaluate the expression pattern and prognostic role of the urokinase-type plasminogen activator (uPA) system in patients who underwent radical nephroureterectomy (RNU) for nonmetastatic upper tract urothelial carcinoma (UTUC). Methods: A total of 732 patients who were treated with RNU for clinically nonmetastatic UTUC comprised our analytical cohort. Immunohistochemical staining of uPA, uPA receptor (uPAR) and uPA inhibitor (PAI-1) was performed using Murine IgG1 monoclonal antibodies. Outcomes of interest were recurrence-free survival, cancer-specific survival, and overall survival. Results: The median age of the patients was 69.8 years and 56.6[%] of them were males. Overall, overexpression of uPA, uPAR, and PAI-1 was observed in 292 (39.9[%]), 346 (47.3[%]), and 345 (47.1[%]) patients, respectively. The uPA system components showed a statistically significant association with adverse clinicopathologic features such as lymphovascular invasion, multifocality, sessile tumors, an